Search the Newsreel

Femasys COO John Canning buys $14,000 in FEMY stock By Investing.com

John Canning, COO of Femasys Inc. (NASDAQ: FEMY), recently purchased 4,375 shares of company stock for $14,000 at $3.20 per share, along with two types of warrants. This transaction occurred while FEMY stock trades near its 52-week low, and InvestingPro analysis suggests the stock …

Suyog Telematics consolidated net profit declines 16.28% in the June 2026 quarter

Femasys chief clinical-medical affairs Mifek buys $10,000 stock

Jeffrey Gerald Mifek, Chief Clinical-Medical Affairs at Femasys Inc. (NASDAQ:FEMY), recently purchased $10,000 worth of common stock and acquired two warrants. The stock purchase was at $3.20 per share, above the current trading price, with one warrant exercisable soon and another tied to significant …

Albemarle (ALB) Earnings Beat Raises A Bigger Question About Value

Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027

Olema Pharmaceuticals' stock fell by 12.90% after the company announced that pivotal breast cancer data for its Phase 3 OPERA-01 trial would be delayed until the first quarter of 2027. Despite this setback, the company presented initial Phase 1 data for OP-3136, showing its …

Femasys Raises $30 Million in Private Placement; Adds Investor Board Rights, Ends Prior Nomination Rights

Femasys (FEMY) has completed a $30 million private placement of common stock and warrants to strengthen liquidity and fund growth. The agreement also includes registration rights for investors and grants Nantahala Capital Management board representation based on ownership thresholds. Concurrently, previous board nomination and …

Femasys CEO Kathy Lee-Sepsick buys $50,000 in FEMY stock

Femasys CEO Kathy Lee-Sepsick purchased 15,625 shares of FEMY stock for $50,000, along with two types of warrants, indicating confidence in the company, especially as the stock trades near its 52-week low. This insider purchase follows recent positive developments for Femasys, including regaining Nasdaq …

H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60

H.C. Wainwright has reaffirmed its Buy rating on Hemab Therapeutics Holdings (COAG.US) and increased its target price to $60. This indicates a positive outlook from the firm regarding the company's future performance and stock valuation.

Gladstone Land Announces Second Quarter 2026 Results

Gladstone Land Corporation reported its financial results for the second quarter ended June 30, 2026, noting a net loss of $8.5 million but an improvement in AFFO per share compared to the prior year. The company highlighted a shift in revenue recognition to primarily …

Fusemachines Inc. Common stock (NASDAQ: FUSE) Share Price, FUSE Stock News, FUSE Share Price & Updates

Albemarle Corp. stock underperforms Tuesday when compared to competitors

Albemarle Corp. (ALB) shares declined by 1.41% on Tuesday, closing at $129.36. This underperformance occurred on a generally down day for the stock market, with both the S&P 500 Index and the Dow Jones Industrial Average also seeing declines. The stock's fall ended a …

Gladstone Land Reports $8.46 Million Net Loss in Q2 2026 with Increased Operating Expenses

Gladstone Land Corporation reported a net loss of $8.46 million for the second quarter of 2026, with a net loss attributable to common stockholders reaching $13.52 million. These figures were disclosed in their Form 10-Q filing with the SEC on August 11, 2026. The …

Gladstone: Q2 Earnings Snapshot

This article provides a brief snapshot of Gladstone's Q2 earnings. It appears to be a placeholder or an article that did not fully load, as no specific financial details or further text are present. The content is limited to the headline and publication time.

Gladstone Land (NASDAQ:LAND) Posts Earnings Results, Misses Expectations By $0.06 EPS

Gladstone Land (NASDAQ:LAND) reported quarterly EPS of ($0.32), missing analyst estimates by $0.06, though revenue of $12.69 million exceeded expectations. The stock is trading near its one-year low, and the company announced a monthly dividend of $0.0467 per share, yielding approximately 6.8%. Analyst sentiment …

Femasys (FEMY) secures $30M private placement with extensive warrant package and board rights

Femasys Inc. has secured a $30 million private placement through the sale of common stock and a significant package of pre-funded and accompanying warrants to accredited investors. The deal includes board designation rights for lead investor Nantahala Capital Management and involves participation from five …

Hemab Therapeutics (COAG) widens loss but builds $457.5M cash war chest

Gladstone Land (NASDAQ: LAND) boosts cash flow while booking Q2 2026 net loss

Gladstone Land Corporation reported a net loss of $8.5 million in Q2 2026, alongside increased cash flow from operations of $19.9 million, a 404.7% year-over-year rise. The company experienced a shift towards participation-based rents on "Repositioned Farms" and significantly reduced its total indebtedness by …

Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at Citigroup

Citigroup has lowered its price target for Olema Pharmaceuticals (NASDAQ:OLMA) to $59.00 but maintained a "buy" rating, indicating a significant potential upside. This adjustment comes as the company reported a larger-than-expected quarterly loss of $0.61 per share. Olema Pharmaceuticals is a clinical-stage biotech focusing …

Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright

HC Wainwright has increased its price target for Hemab Therapeutics (NASDAQ:COAG) to $60.00 from $52.00, maintaining a "buy" rating, which suggests a potential upside of 16.91%. The company has a consensus "Moderate Buy" rating from analysts, with shares recently trading up 2.9% despite missing …

Emera Inc. stock rises Tuesday, outperforms market

Emera Inc. (EMA) stock increased by 0.78% to C$71.24 on Tuesday, outperforming the Canadian market as the S&P/TSX Composite Index rose by 0.05%. The company's shares closed 8.7% below its 52-week high of C$77.99, achieved on July 28th.

ETFs Investing in Braemar Hotels & Resorts, Inc. 5.5 % Cum Conv Pfd Registered Shs Series B Stocks

This article lists Exchange Traded Funds (ETFs) that invest in Braemar Hotels & Resorts, Inc. 5.5% Series B Cumulative Convertible Preferred Stock. It provides a table of funds including their market value, weight, issuer, management style, expense ratio, AUM, price, change percentage, relative volume, …

Suyog Telematics Q1FY27 net profit falls 16.3% to ₹1,449.69 crore

Suyog Telematics Q1 Results: Net profit at ₹1,449.69 crore, dividend approved

Why Bridgemarq Real Estate Services Inc stock is rising today

What's Going On With CEMATRIX Corporation Stock Tuesday?

LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Navigating a 39% Potential Upside in the Healthcare Sector

LeMaitre Vascular, Inc. (LMAT), a healthcare sector player specializing in vascular surgery medical devices, shows a potential upside of 39.33% with an average target price of $113.13. Despite trading below its 50-day and 200-day moving averages, the company exhibits strong operational efficiency, a healthy …

Olema Pharmaceuticals (NASDAQ:OLMA) Shares Gap Down on Disappointing Earnings

Olema Pharmaceuticals (NASDAQ:OLMA) gapped down after reporting Q2 EPS of $(0.61), missing analyst estimates. Despite the disappointing earnings, analyst sentiment remains largely positive with a "Moderate Buy" consensus rating and a $43.90 target price. Institutional investors hold a significant portion of the stock, while …

Olema Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $39.9, Implies 234% Upside

Olema Pharmaceuticals, Inc.'s average 12-month price target has been adjusted to $39.9, down from $40.7, according to estimates from 10 analysts. This new target suggests a potential upside of approximately 234% based on the August 10 closing price. The consensus rating from 11 analysts …

Safe Harbor To Buy MarineMax For $1.5 Billion Cash

Safe Harbor is set to acquire MarineMax for $1.5 billion in cash, uniting two major players in the global yachting industry. This acquisition will combine MarineMax's extensive network of dealerships, marinas, and yacht brands with Safe Harbor's marina and superyacht services, which is owned …

MarineMax Reaches Analyst Target Price

In recent trading, shares of MarineMax Inc (Symbol: HZO) have crossed above the average analyst 12-month target price of $37.33, changing hands for $52.12/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on …

Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss

Hemab Therapeutics (COAG) reported a Q2 net loss of $0.80 per share, which is wider than the FactSet estimate of a $0.56 loss. The company is a clinical-stage biotechnology firm focused on developing therapies for blood coagulation disorders, with lead assets in Phase 1/2 …

Hemab Therapeutics reports Q2 2026 net loss of $24.2M, cash runway into 2029 after $317M IPO proceeds

Hemab Therapeutics reported a Q2 2026 net loss of $24.2 million but maintains a strong cash position of $457.5 million, expected to fund operations into 2029 following $317.2 million from its IPO. The company reiterated key clinical milestones for sutacimig, HMB-002, and the newly …

Intermonte conferma la view su Banca Sistema dopo i conti

RBC cuts Albemarle stock price target on revised earnings outlook

RBC Capital has lowered its price target for Albemarle Corp. (NYSE:ALB) to $157 from $166, while maintaining an Outperform rating, due to revised earnings estimates for the lithium producer. Despite the reduced target, InvestingPro analysis indicates Albemarle remains undervalued with a fair value of …

Handelsbanken Fonder AB Has $81.37 Million Stake in Albemarle Corporation $ALB

Handelsbanken Fonder AB increased its stake in Albemarle Corporation by 14.0% in the second quarter, now owning 602,617 shares valued at $81.37 million. Other institutional investors have also adjusted their holdings, with 92.87% of the company's stock owned by institutional investors and hedge funds. …

Arkema: Disclosure of Trading in Own Shares from 03 August to 07 August 2026

LA DÉFENSE, France, August 11, 2026--(BUSINESS WIRE)--Regulatory News: In accordance with applicable regulations, Arkema (Paris:AKE) announces having carried out the following share buyback transactions in accordance with Article 5 §2 of Regulation (EU) No 596/2014 from 03 August to 07 August 2026 Name of …